Detalhe da pesquisa
1.
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.
Nature
; 619(7968): 160-166, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37258666
2.
Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
J Pharmacol Exp Ther
; 384(3): 331-342, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36241203
3.
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Nature
; 525(7570): 543-547, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26367798
4.
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
J Pharmacol Exp Ther
; 364(3): 494-503, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263244
5.
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
J Pharmacol Exp Ther
; 352(3): 579-89, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25576074
6.
Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.
Nat Med
; 12(5): 568-73, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16648858
7.
Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome.
Mol Cell Proteomics
; 10(11): M111.008540, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21857030
8.
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance.
bioRxiv
; 2023 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36747713
9.
Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle.
Dev Cell
; 12(5): 713-25, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17488623
10.
Molecular requirements for epithelial-mesenchymal transition during tumor progression.
Curr Opin Cell Biol
; 17(5): 548-58, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16098727
11.
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Cancer Discov
; 12(4): 924-937, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35046095
12.
Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.
Oncoimmunology
; 11(1): 2080328, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35756842
13.
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Nat Cancer
; 3(7): 821-836, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35883003
14.
Targeting Son of Sevenless 1: The pacemaker of KRAS.
Curr Opin Chem Biol
; 62: 109-118, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33848766
15.
Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist.
Mol Cancer Ther
; 20(1): 96-108, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33037135
16.
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
J Med Chem
; 64(10): 6569-6580, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33719426
17.
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Cancer Discov
; 11(1): 142-157, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816843
18.
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Curr Biol
; 17(4): 316-22, 2007 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17291758
19.
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
Curr Biol
; 17(4): 304-15, 2007 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17291761
20.
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Mol Cancer Ther
; 19(4): 1059-1069, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32054790